| 证券代码：600673 | 证券简称：东阳光 | 编号：临 | 2025-21 号 | | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | 广东东阳光科技控股股份有限公司 第十二届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 9 日，广东东阳光科技控股股份有限公司（以下简称"公司"） 以通讯方式召开第十二届监事会第四次会议决议，全体监事均对会议议案发表 了意见。会议符合《公司法》及《公司章程》规定。经审议，形成如下决议： 一、审议通过了《公司 2024 年年度报告及摘要》（3 票同意、0 票反对、0 票弃权）； 1、年度报告的编制和审议程序符合法律、法规、公司章程和公司内部管理 制度的各项规定； 该议案需提交股东大会审议。 二、审议通过了《公司 2024 年度监事会工作报告》（3 票同意、0 票反对、 0 票弃权）； 该议案需提交股东大会审议。 三、审议通过了《公司 2024 年度财务决算报告》（3 票 ...

广东东阳光科技控股股份有限公司 （此页无正文，仅为广东东阳光科技控股股份有限公司第十二届董事会独立 董事专门会议第二次会议决议之签字页） 独立董事：覃继伟 第十二届董事会独立董事专门会议 第二次会议决议 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董 事管理办法》（以下简称"《管理办法》"）《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》（以下简称"《规范运作》"）及《广东东阳光科技控股股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，广东东阳光科技控股 股份有限公司（以下简称"公司"）全体独立董事于 2025 年 4 月 9 日以通讯方式 召开第十二届董事会独立董事专门会议第二次会议。应参会独立董事 3 人，实 际参会独立董事 3 人，会议的召集、召开及表决程序符合《公司法》《管理办法》 《规范运作》的有关规定，所做决议合法有效。经与会独立董事审议，一致通过 了如下决议： 一、审议通过了《关于聘请"天健会计师事务所（特殊普通合伙）"为本公 司 2025 年度财务审计和内控审计机构的议案》 经核查，天健会计师事务所（特殊普通合伙）（以下简称"天健"）具备证券 ...

| 证券代码：600673 | 证券简称：东阳光 | | | | 编号：临 2025-20 号 | | --- | --- | --- | --- | --- | --- | | | | | | 01 | | | 债券代码：242444 | | 东科 | 债券简称：25 | | | 广东东阳光科技控股股份有限公司 第十二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 9 日，广东东阳光科技控股股份有限公司（以下简称"公司"） 以通讯方式召开第十二届董事会第十二次会议决议，全体董事均对会议议案发表 了意见。会议符合《公司法》及《公司章程》规定。经审议，形成如下决议： 一、审议通过了《公司 2024 年度报告及摘要》（9 票同意、0 票反对、0 票 弃权）； 与会董事发表了如下确认意见：公司董事会及董事保证公司 2024 年度报告 及摘要中所载资料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 三、审议通过了《公司 2024 年度财 ...

Financial Performance - The company's net profit attributable to shareholders for 2024 is CNY 374,988,008.07, with retained earnings available for distribution amounting to CNY 3,022,928,308.54[6]. - In 2024, the company achieved a revenue of approximately ¥12.20 billion, representing a 12.40% increase compared to ¥10.85 billion in 2023[24]. - The net profit attributable to shareholders was approximately ¥375 million in 2024, a significant recovery from a net loss of approximately ¥294 million in 2023[24]. - The basic earnings per share (EPS) for 2024 was ¥0.13, compared to a loss of ¥0.10 per share in 2023[24]. - The company reported a net cash flow from operating activities of approximately ¥568 million, an increase of 38.56% from ¥410 million in 2023[24]. - The total assets at the end of 2024 were approximately ¥25.36 billion, reflecting a 1.64% increase from ¥24.95 billion at the end of 2023[24]. - The net profit after deducting non-recurring gains and losses was ¥327,427,731.19, an increase of 174.35% year-on-year[82]. - The company achieved operating revenue of ¥12,199,116,451.46, a year-on-year increase of 12.40%[82]. - Total liabilities amounted to ¥15,904,358,976.65, with a debt-to-asset ratio of 62.71%, up 3.36 percentage points from the previous year[82]. Profit Distribution and Retained Earnings - The company plans not to distribute profits or increase capital reserves for 2024, focusing on supporting business operations and liquidity needs[6]. - Cumulative cash dividends over the last three years (2022, 2023, and 2024) total CNY 178,302,670, representing 403.91% of the average distributable profit during this period[6]. - The company has a total of 3,022.93 million RMB in undistributed profits at the end of the last fiscal year, indicating potential for future reinvestment[184]. - The company plans to distribute a cash dividend of 3.36 RMB per 10 shares, amounting to a total cash dividend of approximately 997.62 million RMB for 2023[179]. Research and Development - Significant investments in research and development were made to accelerate technological innovation and product development[31]. - The total R&D investment amounted to ¥514,097,400.36, representing 4.21% of total revenue[94]. - The company has been recognized for its R&D capabilities, having applied for over 50 patents, including awards for its R125 catalyst technology, which has a long operational cycle and lower production costs[67]. - Research and development expenses rose by 19.93% to CNY 514.10 million, reflecting increased investment in R&D[83]. - The number of R&D personnel is 133, making up 1.51% of the total workforce[95]. Market Strategy and Expansion - The company emphasized a strategy of "innovation + internationalization" to enhance market competitiveness and operational efficiency[31]. - The company aims to strengthen collaboration with industry leaders to expand market opportunities and enhance its core competitiveness[31]. - The company is actively expanding into high-value-added sectors such as new energy and new materials, focusing on products like layered foils and lithium batteries[79]. - The company is expanding its liquid cooling business, establishing a comprehensive solution for AI data centers and energy storage applications[41]. - The company plans to strengthen its position in the specialty aluminum foil market by extending its industrial chain and increasing sales efforts in overseas markets[136]. Environmental and Sustainability Efforts - The company has been recognized with 5 national green factory awards, emphasizing its commitment to environmental sustainability[81]. - The company invested 185.49 million CNY in environmental protection during the reporting period[192]. - The company has implemented a comprehensive pollution control system, ensuring all wastewater and emissions meet regulatory standards[198]. - The company has invested in advanced treatment technologies, including a three-level prevention system and emergency pools[200]. Corporate Governance - The board of directors and management confirm the accuracy and completeness of the annual report, with no significant omissions[3]. - The company has implemented a related party transaction decision-making system to prevent fund occupation by major shareholders, maintaining independence in operations[149]. - The supervisory board has effectively monitored the company's operations, internal controls, and compliance, ensuring the legality of actions taken by directors and senior management[149]. - The company has adhered to information disclosure regulations, ensuring timely and accurate communication of information to all shareholders[150]. Risks and Challenges - The company acknowledges potential risks in future plans and strategies, advising investors to be cautious[10]. - The company faces market risks due to global economic uncertainties, which may impact export businesses, and plans to enhance core competitiveness through innovation and cost management[140]. - The company is exposed to policy risks that could negatively affect production and sales in the electrode foil and aluminum electrolytic capacitor industries, particularly if energy consumption policies are implemented[141]. - The company acknowledges R&D investment risks due to uncertainties in the development process and plans to optimize R&D efficiency through talent acquisition and collaboration with leading enterprises[142]. Employee and Management Information - The total number of employees in the parent company is 178, while the main subsidiaries employ 8,585, resulting in a total of 8,763 employees[174]. - The company has established a training management system to ensure all employees receive adequate training, with a focus on continuous development[177]. - The company has a structured compensation plan for its board members and senior management to align with performance metrics[152]. - The company experienced changes in its board and management personnel due to term expirations and personal reasons[153].

Financial Performance Forecast - The company expects a net profit attributable to shareholders for Q1 2025 to be between CNY 253 million and CNY 323 million, representing a year-on-year growth of 156.17% to 227.05%[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between CNY 244 million and CNY 314 million, with a year-on-year growth of 166.25% to 242.63%[4]. - In the same period last year, the net profit attributable to shareholders was CNY 98.76 million, and the profit before tax was CNY 106.08 million[5]. - There are no significant uncertainties affecting the accuracy of this earnings forecast, and the data has not been audited by a registered accountant[9]. - The forecast data is preliminary and the final financial figures will be disclosed in the official Q1 2025 report[10]. Market Dynamics and Business Growth - The significant profit increase is driven by the rising demand for third-generation refrigerants (HFCs) and improved supply-demand dynamics in the market[6]. - The booming data center and energy storage industries have led to a sustained recovery in the demand for electronic components, contributing to a substantial increase in profits from the company's capacitor business[7]. Strategic Initiatives - The company has accelerated its strategic layout in liquid cooling for intelligent computing centers and humanoid robots, establishing joint ventures to integrate resources and develop a complete ecosystem from R&D to market promotion[7]. - The company has implemented a departmental restructuring to enhance integrated management of research, production, and sales, maximizing resource efficiency and synergy[8]. - The company has upgraded its major customer department system to improve operational mechanisms and enhance market responsiveness[8].

关于 2024 年度不进行利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 广东东阳光科技控股股份有限公司（以下简称"公司"）2024 年度拟不 进行利润分配，也不进行资本公积金转增股本。 ● 本次利润分配方案尚需提交公司 2024 年年度股东大会审议。本利润分配 方案不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》第 9.8.1 条 第一款第（八）项规定的可能被实施其他风险警示的情形。 一、 利润分配方案内容 （一）利润分配方案的具体内容 | 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 2025-22 | 号 | | --- | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 | 东科 01 | | | | 广东东阳光科技控股股份有限公司 | 项目 | 本年度 | | 上年度 | 上上年度 | | --- | --- | --- | --- | --- | | 现金分红总额（元） | | 0 ...

Core Viewpoint - The article highlights the growing popularity of freeze-dried fresh cordyceps as a modern health supplement, which is easier to absorb and more convenient to consume compared to traditional dried cordyceps [1][2]. Group 1: Product Comparison - Traditional dried cordyceps has limitations such as high-temperature drying that destroys active ingredients, hard texture, and the need for pre-soaking and cooking, making it less user-friendly [2]. - Freeze-dried fresh cordyceps utilizes low-temperature preservation technology, retaining a higher percentage of active nutrients, particularly key components like SOD, and can be consumed directly or with minimal preparation [2]. Group 2: Quality Standards - The quality of cordyceps is determined by various factors including raw material selection, cleaning, sorting, and packaging, which require professional expertise [4]. - Some brands have established standardized processes for grading based on the integrity of the cordyceps, employing sterile operations for deep cleaning, and conducting thorough quality inspections to ensure safety and traceability [4]. Group 3: Changing Consumer Demographics - The consumer base for cordyceps is expanding, with younger individuals incorporating it into their daily routines, such as making cordyceps tea at work or using it in functional meals [5]. - Cordyceps is being redefined as a part of a healthy lifestyle rather than just a traditional supplement, appealing to those who prioritize quality of life [5]. Group 4: Market Trends - The company Dongyangguang Fresh Cordyceps is developing a more mature sales and collaboration network, recently opening new stores in multiple cities and initiating cooperative plans [6]. - The article suggests that those interested in the health industry should pay attention to the business models and market performance of health supplement products like cordyceps [6].

Core Insights - Dongyangguang Changjiang Pharmaceutical's "inclusion in Stock Connect" is a pivotal topic for 2024, with significant interest from northbound capital since its inclusion last September [1][2] - The company has seen a substantial increase in northbound capital investment, with holdings rising from 11.99% to 25.57% since its inclusion [1] Financial Performance - In 2024, the company reported revenue of 3.724 billion RMB, with a gross profit of 2.794 billion RMB and a net profit attributable to shareholders of 483 million RMB [3] - Research and development (R&D) expenditure reached 493 million RMB, marking a year-on-year increase of 156.62% [3] Product Development - The company's insulin product line generated 137 million RMB in revenue, a significant increase of 101.14% year-on-year, with five insulin products approved for market [4] - The innovative drug HEC88473, a dual agonist for GLP-1/FGF21, has a licensing agreement worth 938 million USD, highlighting the company's strong position in the market [5][7] Market Trends - The global market for GLP-1 drugs is projected to reach 90 billion USD by 2030, indicating a robust growth opportunity for the company [5] - The company’s first innovative drug, Emetine Phosphate Capsules, achieved revenue of 89.49 million RMB, reflecting a 120.06% increase year-on-year [6] Innovation and AI Integration - The company is leveraging AI in drug development, with a focus on enhancing innovation capabilities through advanced AI-driven models [9][10] - A partnership with Huawei Cloud aims to optimize drug molecular properties and streamline the drug discovery process, significantly improving efficiency [11] Strategic Positioning - The company is transitioning towards a growth model centered on innovative drugs and AI healthcare, moving away from traditional pharmaceutical development [12] - Continuous investment from northbound capital indicates a growing recognition of the company's value in the current market environment [12]

证券代码：600673 证券简称：东阳光 编号：临 2025-19 号 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份解质押及质押的公告 | 2、本次股份质押基本情况 | | --- | 截至本公告披露日，公司控股股东深圳市东阳光实业发展有限公司（以 下简称"深圳东阳光实业"）累计质押股数数量为 561,798,054 股，占其持股数量 的 90.96%；控股股东及其一致行动人累计质押股数数量为 1,198,388,597 股，占 合计持股数量比例为 75.46%。 一、本次股份解质押及质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人宜昌药业股份的通知，获悉其将其持有的公司部分无限售流通股 进行了解质押及质押，具体事项如下： 1、本次股份解质押的基本情况 | 股东名称 | 宜昌东阳光药业股份有限公司 | | --- | --- | | 本次解质押股数 | 80,500,000 股 | | 占其所持股份比例 | 14.77% | | 占公司总股本比例 | 2.67% | | 解质押时间 | 2025 年 3 月 18 日 | | 持股数量 | 5 ...